Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis

[1] Martinez-Naharro A(2018)Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types Cardiac amyloidosis. Clin Med (Lond) 18 s30-s35

[2] Hawkins PN(2009)Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction Circulation 120 1203-1212

[3] Fontana M(2015)(18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis Eur Heart J 36 2585-2594

[4] Rapezzi C(2018)Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis J Nucl Cardiol 25 1559-1567

[5] Merlini G(2018)Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N Engl J Med 379 11-21

[6] Quarta CC(2018)Transthyretin cardiac amyloidosis: an update on diagnosis and treatment N Engl J Med 379 1007-1016

[7] Riva L(2019)Nonbiopsy diagnosis of cardiac transthyretin amyloidosis ESC Heart Fail 6 1128-1139

[8] Longhi S(2016)Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy Circulation 133 2404-2412

[9] Leone O(2005)Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis J Am Coll Cardiol 46 1076-1084

[10] González-López E(2019)Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis J Nucl Cardiol 26 1638-1641

[1] Martinez-Naharro A(2018)Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types Cardiac amyloidosis. Clin Med (Lond) 18 s30-s35

[2] Hawkins PN(2009)Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction Circulation 120 1203-1212

[3] Fontana M(2015)(18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis Eur Heart J 36 2585-2594

[4] Rapezzi C(2018)Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis J Nucl Cardiol 25 1559-1567

[5] Merlini G(2018)Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy N Engl J Med 379 11-21

[6] Quarta CC(2018)Transthyretin cardiac amyloidosis: an update on diagnosis and treatment N Engl J Med 379 1007-1016

[7] Riva L(2019)Nonbiopsy diagnosis of cardiac transthyretin amyloidosis ESC Heart Fail 6 1128-1139

[8] Longhi S(2016)Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy Circulation 133 2404-2412

[9] Leone O(2005)Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis J Am Coll Cardiol 46 1076-1084

[10] González-López E(2019)Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis J Nucl Cardiol 26 1638-1641